Cadrenal Therapeutics, Inc. Common Stock

NasdaqCM CVKD

Cadrenal Therapeutics, Inc. Common Stock Price to Book Ratio (P/B) on January 14, 2025

Cadrenal Therapeutics, Inc. Common Stock Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Cadrenal Therapeutics, Inc. Common Stock 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Cadrenal Therapeutics, Inc. Common Stock 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Cadrenal Therapeutics, Inc. Common Stock average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: CVKD

Cadrenal Therapeutics, Inc. Common Stock

CEO	Mr. Quang X. Pham
IPO Date	Jan. 20, 2023
Location	United States
Headquarters	822 A1A North
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key trends

Past 5 years